This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Novartis to Conduct Trial on Obese, Type II Diabetes Patients
by Zacks Equity Research
In a recent announcement, MorphoSys AG mentioned that its partner Swiss major Novartis AG (NVS) will conduct a phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes.
ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk
by Zacks Equity Research
On Jan 13, we issued an updated report on ARIAD Pharmaceuticals, Inc. (ARIA).
Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin regimen patent for its cancer drug Alimta.
Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
by Zacks Equity Research
Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.
Teva Falls on Disappointing 2017 Sales & Earnings Guidance
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) provided a weaker-than-expected sales and earnings guidance for 2017, seeing that its blockbuster multiple sclerosis drug, Copaxone, is reeling under competitive pressures.
Momenta (MNTA) to Receive $50M Under CSL Collaboration
by Zacks Equity Research
Momenta Pharmaceuticals, Inc. (MNTA) entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.
Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication
by Zacks Equity Research
Roche Holding AG (RHHBY) announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis- fifth indication.
Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit
by Zacks Equity Research
Eli Lilly and Company's (LLY) animal health subsidiary Elanco, announced that it has closed the previously announced acquisition of German drugmaker Boehringer Ingelheim's Vetmedica U.S. pet vaccines unit.
Incyte Treats First Patient in Phase II GVHD Study on Jakafi
by Zacks Equity Research
Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.
ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong
by Zacks Equity Research
Shares of ARIAD Pharma surged 98.4% year to date and outperformed the Zacks classified Medical-Drugs industry that declined 25.4%.
Ligand (LGND) Signs Licensing Deals with Ono and Novartis
by Zacks Equity Research
Ligand Pharmaceuticals announced that it has entered into a worldwide license agreement with Ono Pharmaceutical under which Ono will use its OmniAb platform for the discovery of fully human mono- and bispecific antibodies.
Pfizer Ibrance sNDA Accepted by FDA under Priority Review
by Zacks Equity Research
Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) to convert accelerated approval for its breast cancer drug, Ibrance, to regular approval was accepted by the FDA under priority review.
Conatus Stock Up on Liver Drug Collaboration with Novartis
by Zacks Equity Research
Conatus (CNAT) inked an exclusive option, collaboration and license agreement with Novartis (NVS) for the worldwide development and commercialization of emricasan.
Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that it received FDA approval for crisaborole topical ointment to treat mild-to-moderate eczema, or atopic dermatitis, in patients two years and older. The ointment will be sold under the brand name Eucrisa.
Ophthotech Hits 52-Week Low on Unfavorable Fovista Data
by Zacks Equity Research
Ophthotech's (OPHT) shares tumbled 86.4% to a 52-week low after the company reported disappointing phase III data on its eye drug, Fovista, in wet AMD patients.
Novartis Offers Positive Data on Breast Cancer Drug LEE011
by Zacks Equity Research
Novartis (NVS) announced results from the phase III MONALEESA-2 study on LEE011 for the treatment of first-line HR+/HER2- advanced breast cancer.
Teva Copaxone EU Label to Omit Pregnancy Contraindication
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU.
Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
by Zacks Equity Research
Novartis (NVS) announced results from the phase III ASCEND-4 study on Zykadia, for the treatment of patients with advanced ALK+ NSCLC.
Incyte Jakafi Positive in Pooled Analysis of Five-Year Data
by Zacks Equity Research
Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.
ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.
by Zacks Equity Research
ARIAD Pharmaceuticals, Inc. (ARIA) announced that the FDA has granted a full approval to its leukemia drug, Iclusig (ponatinib), following its successful completion of the commitments made on accelerated approval in Dec 2012.
Company News for November 22, 2016
by Zacks Equity Research
Companies In The News: TSN,FB,NVS,LOCK,SYMC